Больные бронхиальной астмой, перенесшие COVID-19


DOI: https://dx.doi.org/10.18565/pharmateca.2021.5.76-80

Е.Ю. Трушина, Е.М. Костина, Е.А. Орлова

Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО РМАНПО Минздрава РФ, Пенза, Россия
Обоснование. Коронавирусная инфекция 2019 г. (COVID-19) распространена во всем мире. Значение бронхиальной астмы (БА) на течение COVID-19 неоднозначно.
Цель исследования: ретроспективно проанализировать течение инфекции COVID-19 у больных БА.
Методы. Проведен анализ документации 1167 пациентов с диагнозом COVID-19, среди них 82 (7,02%) пациента страдали БА.
Результаты. Среди больных БА, перенесших инфекцию COVID-19, мужчин было 11 (13,4%) , женщин – 71 (86,6%). Среди больных БА сахарный диабет встречался у 5 (6,09%) человек, артериальная гипертензия у 70 (85,4%), ишемическая болезнь сердца у 8 (9,75%). Среди больных БА умерли 5 человек. Курящие больные БА составили 7 человек.
Заключение. Проведенный анализ показал, что распространенность БА составляла 7,02% от общего числа инфекций COVID-19. Выявлена низкая смертность среди больных БА, инфицированных COVID-19.

Литература


1. van Doremalen N., Bushmaker T., Morris D.H., et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–67. Doi: 10.1056/NEJMc2004973.


2. Richardson S., Hirsch J.S., Narasimhan M., et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–59. Doi: 10.1001/jama.2020.6775.


3. Arentz M., Yim E., Klaff L., et al. Characteristics and Outcomes of 21Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;323(16):1612–14.


4. Chhiba K.D., Patel G.B., Vu T.H., et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(2):307–14. Doi: 10.1016/j.jaci.2020.06.010.


5. Li X., Xu S., Yu M., et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–18. Doi: 10.1016/j.jaci.2020.04.006.


6. Johnston S.L. Asthma and COVID-19: Is asthma a risk factor for severe outcomes? Allergy. 2020;75(7):1543–45. doi: 10.1111/all.14348.


7. Guia para el manejo del asma GEMA5.0. Available at: http://www.gemasma.com. Access date: 22.03.2021.


8. Bhatraju P.K., Ghassemieh B.J., Nichols M., Kim R., et al. Covid-19 in Critically Ill Patients in the Seattle Region – Case Series. N Engl J Med. 2020:382(21):2012–22. Doi: 10.1056/NEJMoa2004500.


9. Garg S., et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1-30, 2020. MMWR. Morb Mortal Wkly Rep. 2020;69(15):458–64. Doi: 10.15585/mmwr.mm6915e3.


10. Myers L.C., Parodi S.M., Escobar G.J., Liu V.X. Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. JAMA. 2020;323(21):2195–98. Doi: 10.1001/jama.2020.7202.


11. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China, 2020. China CDC weekly. February 17 2020.


12. Grasselli C., Zangrillo A., Zanella A., et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574–81. Doi: 10.1001/jama.2020.5394.


13. Guan W.J., Liang W.H., Zhao Y., et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. Doi: 10.1183/13993003.00547-2020.


14. Zhang J.J., Dong X., Cao Y.Y., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–41. doi.org/10.1111/all.14238


15. Dembic Z. Chapter 6 – cytokines of the immune system: interleukins. In: Dembic Z. (ed). The cytokines of the immunesystem. Amsterdam, Academic Press, 2015. Р. 143–239. Doi: 10.1016/B978-0-12-419998-9.00006-7.


16. te Velde A.A., Huijbens R.J., Heije K., et al. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosisfactor alpha, and IL-6 by human monocytes. Blood. 1990;76(7):1392–97.


17. Levings M.K., Schrader J.W. IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and - independent mechanisms. J Immunol. 1999;162(9):5224–29.


18. de Vries J.E. The role of IL-13 and its receptor in allergy andinflammatory responses. J Allergy Clin Immunol. 1998;102(2):165–69. Doi: 10.1016/s0091-6749(98)70080-6.


19. Pilette C., Ouadrhiri Y., Van Snick J., et al. IL-9 inhibits oxidative burst and TNF-alpha release in lipopolysaccharide-stimulated human monocytesthrough TGF-beta. J Immunol. 2002;168(8):4103–11. Doi: 10.4049/jimmunol.168.8.4103.


20. Временные методические рекомендации по профилактике,диагностике и лечению новой коронавирусной инфекции (COVID-19). Версия 9 (26.10.2020). (Электронный ресурс).


21. Jackson D.J., Busse W.W., Bacharier L.B., et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203–6. Doi: 10.1016/j.jaci.2020.04.009.


22. Halpin D.M., Singh D., Hadfield R.M. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55(5):2001009. Doi: 10.1183/13993003.01009-2020.


23. Dong X., Cao Y.Y., Lu X.X., et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7):1699–709. Doi: 10.1111/all.14289.


24. Arden K.E., Chang A.B., Lambert S.B., et al. Newly identified respiratory viruses in children with asthma exacerbation not requiring admission to hospital. J Med Virol. 2010;82:1458–61. Doi: 10.1002/jmv.21819.


25. Johnston S.L., Pattemore P.K., Sanderson G., et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med. 1996;154:654–60. Doi: 10.1164/ajrccm.154.3.8810601.


26. Khetsuriani N., Kazerouni N.N., Erdman D.D., et al. Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol. 2007;119:314–21. Doi: 10.1016/j.jaci.2006.08.041.


27. Rosenberg H.F., Dyer K.D., Domachowske J.B. Respiratory viruses and eosinophils: exploring the connections. Antivir Res. 2009;83(1):1–9. Doi: 10.1016/j.antiviral.2009.04.005.


28. Rosenberg H.F., Dyer K.D., Domachowske J.B. Eosinophil sand their interactions with respiratory virus pathogens. Immunol Res. 2009;43(1–3):128–37. Doi: 10.1007/s12026-008-8058-5.


29. Du Y., Tu L., Zhu P., et al. Clinical features of 85 fatal casesof COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med. 2020;201:1372–9. Doi: 10.1164/rccm.202003-0543OC.


30. Hassani M., Leijte G., Bruse N., et al. Diffe-rentiation and activation of eosinophils in the human bone marrow during experimental human endotoxemia. J Leukoc Biol. 2020;108(5):1665–71. Doi: 10.1002/JLB.1AB1219-493R.


31. Butterfield J.H. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin North Am. 2007;27:493–518. Doi: 10.1016/j.iac.2007.06.003.


Об авторах / Для корреспонденции


Автор для связи: Е.Ю. Трушина, к.м.н., ассистент кафедры пульмонологии и фтизиатрии, Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО РМАНПО Минздрава РФ, Пенза, Россия; trushina.lena@mail.ru
Адрес: 440060, Россия, Пенза, ул. Стасова, 8А


ORCID/eLibrary SPIN: 
Е.Ю. Трушина, http://orcid.com/0000-0001-5673-9195; eLibrary SPIN: 2164-6580
Е.М. Костина, http://orcid.com/000-0003-1797-8040; eLibrary SPIN: 2111-8827
Е.А. Орлова, http://orcid.com/0000-0003-1402-2940; eLibrary SPIN: 1700-4848


Похожие статьи


Бионика Медиа